Ge Long Hui·2026-02-24 11:45Core Viewpoint - Fosun Pharma has entered into multiple licensing agreements for its product, Sruvelizumab injection, with KGBio and Abbott, expanding its commercialization rights in various regions [1] Group 1: Licensing Agreements - On September 30, 2019, Fosun Pharma's subsidiary, Fuhong Hanlin, signed an exclusive licensing agreement with KGBio for Sruvelizumab injection in Southeast Asia, the Middle East, and North Africa [1] - On August 25, 2023, Fuhong Hanlin and KGBio signed a revised exclusive licensing agreement, which included the termination of the 2023 agreement for certain regions [1] - On December 31, 2024, Fuhong Hanlin entered into a licensing agreement with Abbott for exclusive commercialization rights in Latin America and the Caribbean [1] Group 2: Agreement Modifications - On February 24, 2026, Fuhong Hanlin and KGBio signed a termination agreement, ending the exclusive commercialization rights for KGBio in all regions except Indonesia [1] - The same day, Fuhong Hanlin and Abbott amended the 2024 licensing agreement to expand the licensed regions and include additional regulatory and sales milestone payments [1]